Health policy decision makers and public funders are faced with the challenge of making choices for health investments to improve the healthy life expectancy of Europeans within the context of constrained resources. Health investments relate to any new technology for the diagnosis, prevention or treatment of disease. Public funders sometimes, but increasingly, evaluate the impact of health investments, but there is a lack of standardised procedures and criteria. This is even more the case for investments related to screening and diagnosis of disease.
The objectives of this study were: 1. to assess existing procedures and criteria used in decision making about health investments for genetic screening; 2. to set up a set of common criteria for the evaluation of health investments related to screening and diagnosis (HISD) in Europe; 3. to guide the better alignment of procedures between all Member States; and 4. to improve the effectiveness and cost-effectiveness of future HISD.
Role of U4 partners
Ghent University was coordinator of the project and responsible for the literature review on health technology assessment for personalized medicines, as well as for the final report on de development of the specific toolkit for decision makers. The University of Groningen was responsible for the draft toolkit and for testing the toolkit with decision makers.
University of Groningen